CI 1998
Alternative Names: CI-1998; CNS therapeutics - CasInvent PharmaLatest Information Update: 11 Nov 2025
At a glance
- Originator Masaryk University
- Developer CasInvent Pharma
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Casein kinase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease